BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NOMAD Bioscience Announces Broad License Agreement


9/29/2008 8:25:41 AM

MUNICH, Germany, Sept. 29 /PRNewswire/ -- Nomad Bioscience GmbH announces that it entered into a broad licensing agreement with Bayer Innovation GmbH and Icon Genetics group. It provides Nomad access to Icon's proprietary technology platforms, including its transient expression technology magnICON(R), for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The agreement provides Nomad with a strategically needed freedom to operate in its core business areas. The financial terms of the agreement are not disclosed.

"Icon Genetics' proprietary gene transfer systems provide a broad solution to the upstream part of manufacturing, and combined with Nomad downstream technologies, they should result in a superior fully integrated process for most of our intended product candidates," said Dr. Yuri Gleba, the founder of Nomad Bioscience. Prof. Dr. Gleba is also co-inventor of Icon's technologies as well as co-founder and managing director of Icon Genetics.

"Icon has developed new generation production platforms that are by far more effective than those commercialized today. Since our own strategic focus is on proprietary biopharmaceuticals, we were looking for a partner who could best apply our proprietary expression methods to other new classes of products," said Dr. Detlef Wollweber, Managing Director of Bayer Innovation.

About Nomad Bioscience:

Nomad Bioscience, headquartered in Munich, is a private start-up biotechnology company developing a series of high value materials such as nanopatterned materials, protein scaffolds, proteins and enzymes for important markets including biosimilar biopharmaceuticals, electric batteries and biofuels.

CONTACT: Prof. Dr. Yuri Gleba of Nomad Bioscience GmbH, +49-345-555-9887,
gleba@nomadbioscience.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES